Key Takeaway: BioCryst reported strong financial results for the second quarter of 2026, with total net revenue of $218.3 million and ORLADEYO net revenue of $158.2 million. The company achieved an operating profit of $98.5 million and a Non-GAAP operating profit of $113.2 million. Additionally, BioCryst maintained its revenue guidance for ORLADEYO and increased its total revenue guidance for the year.
Market Sentiment Analysis
POSITIVE FACTORS
Total net revenue reached $218.3 million.
ORLADEYO net revenue was $158.2 million.
Operating profit stood at $98.5 million.
Full Year 2026 revenue guidance was maintained and increased.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
2.6%
average across 4 past catalysts
Lead asset
Peramivir
Phase 3 · Influenza
Full Press Release Details
— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690
Frequently Asked Questions
What was BioCryst's total net revenue for Q2 2026?
BioCryst reported a total net revenue of $218.3 million for Q2 2026.
How much revenue did ORLADEYO generate in Q2 2026?
ORLADEYO generated $158.2 million in revenue during Q2 2026.
What was the operating profit for BioCryst in Q2 2026?
BioCryst achieved an operating profit of $98.5 million in Q2 2026.
Did BioCryst change its revenue guidance for 2026?
Yes, BioCryst maintained its ORLADEYO revenue guidance and increased total revenue guidance.